Sarepta Therapeutics(US:SRPT)2026-01-12 17:05Financial Performance - Preliminary total net product revenue of $369.6 million for Q4 2025 and $1.86 billion for full-year 2025[4] - ELEVIDYS net product revenue reached $110.4 million for Q4 2025 and $898.7 million for full-year 2025[5] - PMO net product revenues totaled $259.2 million for Q4 2025 and $965.6 million for full-year 2025[5] - The company achieved durable revenue of $965.6 million from its PMO franchise, indicating strong performance[3] Cash Position - As of December 31, 2025, the company had approximately $953.8 million in cash, cash equivalents, restricted cash, and investments[6] Sales Guidance - The company reaffirmed a yearly sales floor of $500.0 million for ELEVIDYS, with intentions to exceed it[7] Market Challenges - The fourth quarter revenue for ELEVIDYS was impacted by a severe flu season and rescheduling of patient infusions[3] Future Plans - The company plans to invest fully in approved therapies and advance its next-generation siRNA pipeline in 2026[6] - The company is focused on expanding its portfolio in precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy[22] Reporting Timeline - The final and complete financial results for Q4 and full-year 2025 will be reported in late February 2026[7]